Enhanced umbilical cord adherent stem cell therapy (CHA Biotech)

N/A

Report date: 2025/03/24 16:34:47

Base Information

Drug NameEnhanced umbilical cord adherent stem cell therapy (CHA Biotech)
Drug Alias NameAllogeneic Umbilical Cord-derived Mesenchymal Stem Cell TherapyHuman umbilical cord derived mesenchymal stem cell therapyCordSTEM-ASCordSTEM-ARDSCordSTEM-CD +[11] 
ClassificationCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsUpdating
Therapy Area/IndicationsLow Back PainPrimary Ovarian InsufficiencyCerebral Infarction +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCHA Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCHA Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsLow Back PainPrimary Ovarian InsufficiencyIntervertebral Disc Degeneration
Inactive IndicationsCerebral Infarction

Other Information

ATC CodeN/A
Related LinksN/A